Hikma announces exclusive agreement with AFT Pharmaceuticals for injectable non-opioid pain medication Combogesic® IV in the US

Rhea-AI Summary

Hikma Pharmaceuticals PLC has signed an exclusive license and distribution agreement with AFT Pharmaceuticals for Combogesic^® IV, a non-opioid intravenous pain relief medication. This agreement grants Hikma exclusive rights to market and distribute the product in the US, which is designed for post-operative use. AFT plans to file for FDA approval in the upcoming months. Hikma aims to expand its portfolio in non-opioid pain management, enhancing access to high-quality medicines for patients and healthcare providers in the US.

Positive

• Exclusive rights for sales and distribution of Combogesic IV in the US.
• Expansion into the growing therapeutic area of non-opioid pain management.

Negative

• None.

LONDON, April 28, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialisation of Combogesic^® IV, the US trade name of Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine.

The licensing agreement provides Hikma with exclusive rights for the sales, marketing and distribution of Combogesic^® IV in the US.  Combogesic^® IV (paracetamol 1000mg + ibuprofen 300mg solution for infusion) is a patented intravenous formulation developed as a line extension to Maxigesic tablets, for use post-operatively in hospitals when patients cannot take a medicine orally. AFT expects to file Combogesic^® IV for approval with the US FDA in the coming months.

"We are pleased to enter into this partnership with AFT for Combogesic^® IV, an important alternative for the treatment of post-operative pain," said Riad Mishlawi, President, Hikma Injectables. "This agreement is another example of how Hikma is continuing to expand its pipeline in growing therapeutic areas like non-opioid pain management treatments, and highlights the importance of partnerships in expanding our ability to offer a broad portfolio of high-quality medicines to US patients, physicians and hospitals."

Enquiries      
Hikma Pharmaceuticals PLC          

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 7776 477050 uk-investors@hikma.uk.com
Steve Weiss David Belian US Communications and Public Affairs	+1 732 720 2830/ +1 732 788 8279 +1 732 720 2814/+1 848 254 4875 uscommunications@hikma.com

About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

View original content:http://www.prnewswire.com/news-releases/hikma-announces-exclusive-agreement-with-aft-pharmaceuticals-for-injectable-non-opioid-pain-medication-combogesic-iv-in-the-us-301279371.html

SOURCE Hikma Pharmaceuticals USA Inc.

FAQ

What is Combogesic IV and its significance for Hikma Pharmaceuticals?

Combogesic IV is a patented intravenous pain relief medication developed by AFT Pharmaceuticals, providing an opioid-free option for post-operative pain management. This agreement allows Hikma Pharmaceuticals to expand its product offerings in the US market.

When does Hikma plan to start marketing Combogesic IV?

Hikma plans to begin marketing Combogesic IV following AFT Pharmaceuticals' filing for FDA approval, expected in the coming months.

How does the exclusive agreement with AFT Pharmaceuticals impact Hikma's business?

The exclusive agreement enhances Hikma's portfolio in the non-opioid pain management market, aiming to provide high-quality treatment options for patients in the US.

What are the components of Combogesic IV?

Combogesic IV consists of paracetamol 1000mg and ibuprofen 300mg, formulated for intravenous infusion.

What is the stock symbol for Hikma Pharmaceuticals?

Hikma Pharmaceuticals is traded under the stock symbols HKMPF and HKMPY.